Surveillance for hepatocellular carcinoma

Cristina Della Corte, Massimo Colombo

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The only hope for a cure from hepatocellular carcinoma (HCC) rests on early diagnosis as it can be attained through semiannual surveillance with abdominal ultrasound (US) of patients at risk. While the strategy of semiannual screening rests on the growth rate of the tumor that in cirrhotic patients takes 6 months to double its volume, on average, the noninvasive radiological diagnosis of HCC is possible in cirrhotic patients with a de novo HCC and patients with chronic hepatitis B. More recently, metabolic diseases related to insulin resistance, including diabetes and obesity, have been recognized to be causally related to HCC as well, in most patients bridging HCC to the histopathological diagnosis of non-alcoholic steatohepatitis (NASH). While the endpoint of an early diagnosis is achieved quite easily in most patients with >1 cm HCC by computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating the specific pattern of an intense contrast uptake during the arterial phase (wash-in) and contrast wash-out during the venous/delayed phase, nodules

Original languageEnglish
Pages (from-to)384-398
Number of pages15
JournalSeminars in Oncology
Volume39
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Hepatocellular Carcinoma
Early Diagnosis
Metabolic Diseases
Chronic Hepatitis B
Fatty Liver
Insulin Resistance
Obesity
Tomography
Magnetic Resonance Imaging
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Surveillance for hepatocellular carcinoma. / Della Corte, Cristina; Colombo, Massimo.

In: Seminars in Oncology, Vol. 39, No. 4, 08.2012, p. 384-398.

Research output: Contribution to journalArticle

Della Corte, Cristina ; Colombo, Massimo. / Surveillance for hepatocellular carcinoma. In: Seminars in Oncology. 2012 ; Vol. 39, No. 4. pp. 384-398.
@article{49d22469a42d4cc48acdd0fb53344188,
title = "Surveillance for hepatocellular carcinoma",
abstract = "The only hope for a cure from hepatocellular carcinoma (HCC) rests on early diagnosis as it can be attained through semiannual surveillance with abdominal ultrasound (US) of patients at risk. While the strategy of semiannual screening rests on the growth rate of the tumor that in cirrhotic patients takes 6 months to double its volume, on average, the noninvasive radiological diagnosis of HCC is possible in cirrhotic patients with a de novo HCC and patients with chronic hepatitis B. More recently, metabolic diseases related to insulin resistance, including diabetes and obesity, have been recognized to be causally related to HCC as well, in most patients bridging HCC to the histopathological diagnosis of non-alcoholic steatohepatitis (NASH). While the endpoint of an early diagnosis is achieved quite easily in most patients with >1 cm HCC by computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating the specific pattern of an intense contrast uptake during the arterial phase (wash-in) and contrast wash-out during the venous/delayed phase, nodules",
author = "{Della Corte}, Cristina and Massimo Colombo",
year = "2012",
month = "8",
doi = "10.1053/j.seminoncol.2012.05.002",
language = "English",
volume = "39",
pages = "384--398",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Surveillance for hepatocellular carcinoma

AU - Della Corte, Cristina

AU - Colombo, Massimo

PY - 2012/8

Y1 - 2012/8

N2 - The only hope for a cure from hepatocellular carcinoma (HCC) rests on early diagnosis as it can be attained through semiannual surveillance with abdominal ultrasound (US) of patients at risk. While the strategy of semiannual screening rests on the growth rate of the tumor that in cirrhotic patients takes 6 months to double its volume, on average, the noninvasive radiological diagnosis of HCC is possible in cirrhotic patients with a de novo HCC and patients with chronic hepatitis B. More recently, metabolic diseases related to insulin resistance, including diabetes and obesity, have been recognized to be causally related to HCC as well, in most patients bridging HCC to the histopathological diagnosis of non-alcoholic steatohepatitis (NASH). While the endpoint of an early diagnosis is achieved quite easily in most patients with >1 cm HCC by computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating the specific pattern of an intense contrast uptake during the arterial phase (wash-in) and contrast wash-out during the venous/delayed phase, nodules

AB - The only hope for a cure from hepatocellular carcinoma (HCC) rests on early diagnosis as it can be attained through semiannual surveillance with abdominal ultrasound (US) of patients at risk. While the strategy of semiannual screening rests on the growth rate of the tumor that in cirrhotic patients takes 6 months to double its volume, on average, the noninvasive radiological diagnosis of HCC is possible in cirrhotic patients with a de novo HCC and patients with chronic hepatitis B. More recently, metabolic diseases related to insulin resistance, including diabetes and obesity, have been recognized to be causally related to HCC as well, in most patients bridging HCC to the histopathological diagnosis of non-alcoholic steatohepatitis (NASH). While the endpoint of an early diagnosis is achieved quite easily in most patients with >1 cm HCC by computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating the specific pattern of an intense contrast uptake during the arterial phase (wash-in) and contrast wash-out during the venous/delayed phase, nodules

UR - http://www.scopus.com/inward/record.url?scp=84864453450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864453450&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2012.05.002

DO - 10.1053/j.seminoncol.2012.05.002

M3 - Article

C2 - 22846857

AN - SCOPUS:84864453450

VL - 39

SP - 384

EP - 398

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -